Date: 2014-08-04
Type of information: Licensing agreement
Compound: Respiratory Syncytial Virus (RSV) drug program
Company: Medivir (Sweden) Boehringer Ingelheim (Germany)
Therapeutic area: Infectious diseases
Type agreement:
Action mechanism:
Disease: Respiratory Syncytial Virus (RSV) infection
Details: * On August 4, 2014, Medivir announced that it has entered a license agreement with Boehringer Ingelheim International GmbH for exclusive, global rights to a drug program for the treatment and prevention of Respiratory Syncytial Virus (RSV) infection. The program includes novel compounds that inhibit the RSV fusion protein, which is a key mediator of viral entry into host cells and a target for new medicines. Under the terms of the agreement Medivir receives an exclusive, global license to research, develop, manufacture and commercialise RSV drugs resulting from Boehringer Ingelheim’s program. Boehringer Ingelheim receives an upfront payment and future success milestones as well as royalties on sales.
Financial terms: Financial details remained undisclosed.
Latest news:
